论文部分内容阅读
目的比较胰岛素类似物和重组人胰岛素治疗成人2型糖尿病的疗效和安全性。方法45例T2DM患者,分别给予超短效胰岛素类似物加长效胰岛素类似物或基因重组正规人胰岛素加精蛋白锌胰岛素强化治疗9个月,比较A1C、平均PG的达标率、低血糖和严重低血糖的发生率,体重增加及胰岛素的用量。结果两组糖尿病患者的PG、A1C均得到了控制,A1C降低类似物组(-2.89±0.054)%;胰岛素组(-2.32 4±0.052)%差异均有统计学意义。类似物组有更多患者血糖达到控制范围内,两组分别是73.91%和45.45%,差异有统计学意义。两组低血糖的发生率分别是18%和22%、两组间体重增加、胰岛素用量无统计学意义。结论类似物组和胰岛素组均能有效的降低血糖,类似物组A1C降低更多,不增加低血糖的发生,有更好的血糖改善。
Objective To compare the efficacy and safety of insulin analogues and recombinant human insulin in the treatment of type 2 diabetes in adults. Methods Forty-five patients with T2DM were treated with intensive insulin analogues or extended-regimen insulin analogues or recombinant human insulin plus proteoglycan insulin for 9 months. The A1C, mean PG compliance, hypoglycemia and severe low The incidence of blood sugar, weight gain and insulin dosage. Results PG and A1C in both diabetic patients were controlled, with A1C reducing analogue group (-2.89 ± 0.054)%; and insulin group (-2.32 4 ± 0.052)% difference being statistically significant. In the analog group, more patients had blood glucose levels within the control range of 73.91% and 45.45%, respectively, with significant differences between the two groups. The incidence of hypoglycemia in both groups was 18% and 22%, respectively. There was no significant difference in the amount of insulin between the two groups. Conclusion Both analog group and insulin group can effectively reduce blood glucose, and A1C in analog group reduces more, does not increase the occurrence of hypoglycemia, and has better blood sugar improvement.